Compare NATH & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NATH | ENGN |
|---|---|---|
| Founded | 1916 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Restaurants | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.6M | 379.3M |
| IPO Year | N/A | N/A |
| Metric | NATH | ENGN |
|---|---|---|
| Price | $96.58 | $8.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $22.71 |
| AVG Volume (30 Days) | 53.0K | ★ 331.3K |
| Earning Date | 02-05-2026 | 12-19-2025 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | ★ 4.02 | N/A |
| EPS | ★ 5.56 | N/A |
| Revenue | ★ $154,991,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.66 | ★ N/A |
| Revenue Growth | ★ 7.82 | N/A |
| 52 Week Low | $75.15 | $2.65 |
| 52 Week High | $118.50 | $11.14 |
| Indicator | NATH | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 51.14 | 56.36 |
| Support Level | $93.82 | $7.57 |
| Resistance Level | $99.07 | $8.47 |
| Average True Range (ATR) | 3.21 | 0.64 |
| MACD | 1.07 | -0.00 |
| Stochastic Oscillator | 76.07 | 63.69 |
Nathan's Famous Inc is an owner of fast food franchises in the United States. The company's reportable segment includes the Branded Product Program, Product licensing, Restaurant operations and Corporate. Branded Product Program derives revenue principally from the sale of hot dog products either directly to foodservice operators or to various foodservice distributors who resell the products to foodservice operators. It generates maximum revenue from the Branded Product Program segment. Geographically, it derives a majority of revenue from the United States.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.